SFI
BHVN

Susquehanna Fundamental Investments’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,500
Closed -$758K – 1771
2021
Q4 		$758K Buy
+5,500
New +$699K 0.02% 761

Other funds holding BHVN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Susquehanna Fundamental Investments's BHVN Position: Q1 2022 in Review

Susquehanna Fundamental Investments sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 5,500 shares — an estimated $758K sold.

Susquehanna Fundamental Investments first reported a position in BHVN in Q4 2021 and held it in 1 quarter. The position peaked at $758K in Q4 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

  • Susquehanna Fundamental Investments reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 5,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $758K.
  • Susquehanna Fundamental Investments first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2021 and held it in 1 quarter.
  • Susquehanna Fundamental Investments's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $758K in Q4 2021.
  • 307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2022, filed 16 May 2022.